Deal round-up 08/05/03

Trinity backs E11.5m AePONA round; German VCs buy into semiconductor business; Viventures in broadband access investment; DVC backs Epigenomics third round; Nordic firms back Bone Support

Trinity backs E11.5m AePONA round


AePONA, the Belfast-based software company backed by Gilbert Little and Jay Murray, has raised E11.5m from Trinity Venture Capital, Amadeus Capital Partners and Invest Northern Ireland, to fund the development and marketing of a new product targeting telecom operators.


AePONA has developed Causeway, a product which allows telecom operators to run other applications on its networks. Causeway is designed to enable operators to plug in and out of other software products, helping to reduce costs. AePONA was spun-off from Apion after the latter was sold to in 1999.


German VCs buy into semiconductor business


Xignal Technologies, a leading intellectual property solutions provider for the semiconductor industry, has closed a second round of funding at E10m. The round was jointly-led by Baytech Venture Capital and Atila Ventures/ETV Beteiligungs GmbH, with follow-on investment from existing backers Benchmark Capital and Star Ventures


Xignal was set up in Munich in 1999 by Yousif Ammar, Miki Moyal and Martin Groepl, previously at Infineon. Xignal had previously raised $7m in December 2000 from Benchmark Capital and Star Ventures. 


In addition to extending Xignal's product portfolio, the funding will be used to increase worldwide sales and business development activities in Europe, the US and South East Asia.


Viventures in broadband access investment


Paris-based OneAccess Networks, a developer of broadband access solutions for telecoms carriers and corporate networks, has landed a further E4.5m from its existing backers, comprising Viventures, AGF Private Equity, and CIC Finance, CIC Capital Privé.


The funding will support OneAccess market expansion, and the design and development of products. The transaction is the first undertaken by Viventures since it was announced last month that Global Asset Capital would take over the management of the Vivendi venture unit.


DVC backs Epigenomics third round


German-based Deutsche Venture Capital (DVC) has committed E5m to a third round financing for Epigenomics a biotech company developing DNA products for early detection and molecular classification of cancer and other diseases. Also investing in the round are 3i, Abingworth, MPM Capital The Wellcome Trust Limited.


DVC first invested in the Berlin-headquartered business in 1999, a year after the company was formed. Since then, the company has raised over E56m in venture capital funding, and has grown from a five-member founding team to a transatlantic biotech company with a total of 135 staff members in Berlin and Seattle.


Nordic firms back Bone Support


Nordic venture capital firms InnovationsKapital (Sweden) and Teknoinvest (Norway) have participated in a $5m financing round for Bone Support, a Swedish biotech company. The transaction is the first round of external financing for Bone Support.


Bone Support, which has developed a product platform for injectable bone materials, will use the investment for the development of its first product SpineSupport, intended for the use in osteoporotic vertebral fractures. SpineSupport is expected to begin clinical trials in the near future.


As part of the transaction, Gunnar Fernström and Johan Rask, both of Innovationskapital, and Andreas Mollatt and Steinar Engelsen of Teknoinvest, will join the Bone Support board.